Injectable EMD-Cell Composition for Gingival Soft Tissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current surgical procedures for soft tissue reconstruction in the craniomaxillofacial complex, particularly for patients with thin gingival biotypes, are invasive and carry a high risk of secondary infection and inflammatory complications, with limited success in achieving ideal functional and aesthetic outcomes.
Innovation Solution
A minimally-invasive composition comprising purified enamel matrix derivative proteins and human fibroblasts or periodontal ligament cells, optionally with additional ECM proteins, administered via injection or hydrodissection, to promote soft tissue growth and healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical procedures are used for soft tissue reconstruction, then tissue availability and closure of defects are improved, but trauma and risk of secondary infection increase
Solution Approach 1:
The patent uses a composition comprising enamel matrix derivative (EMD) proteins and human fibroblasts or periodontal ligament cells as an intermediary substance that can be injected directly into the defect site. This eliminates the need for surgical harvesting of tissue flaps while providing the necessary cells and growth factors to promote tissue regeneration and closure of defects, thereby reducing trauma and infection risk associated with traditional surgical procedures
2Quantity of substance
If local flap harvests are used to increase tissue availability, then closure of defects is improved, but functional and aesthetic goals are not ideally met
Solution Approach 1:
The patent applies local quality by delivering a concentrated composition of EMD proteins and specific cell types (fibroblasts or periodontal ligament cells) directly to the defect site. This localized delivery ensures that the regenerative process occurs precisely where needed, with the EMD proteins providing site-specific signals for tissue formation that match the functional and aesthetic requirements of the oral cavity, rather than relying on general tissue flaps from distant sites
3Reliability
If traditional surgical methods are used for gingival reconstruction, then tissue replacement is achieved, but treatment time and recovery period are extended
Solution Approach 1:
The patent employs preliminary action by pre-culturing human fibroblasts or periodontal ligament cells and combining them with EMD proteins in a ready-to-inject composition. This pre-prepared formulation contains all necessary components for tissue regeneration in optimal concentrations, eliminating the need for lengthy surgical procedures and extended recovery periods. The composition can be injected directly into the defect site and begins promoting tissue regeneration immediately, significantly reducing overall treatment time while maintaining reliable tissue replacement outcomes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition enhances soft tissue regeneration with reduced trauma and infection risk, improving tissue quality and treatment outcomes for thin gingival biotypes, including gingival thickening, recession treatment, and peri-implantitis prevention.
Implementation Method 1
The composition enhances soft tissue regeneration with reduced trauma and infection risk
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a pharmaceutical, dental and/or cosmetic composition comprising a cell culture population of human fibroblasts (hPFB) and/or human periodontal ligament cells (hPDL), and purified and/or isolated enamel matrix derivative (EMD) proteins, which have a molecular weight between 1-160kDa and its use in treating patients suffering from a gingival deficiency and/or disorder, in particular such patients suffering from a gingival deficiency and/or disorder selected from the group consisting of gingival thin biotype, gingival recession and enlargement and gingival papilla regeneration. Preferably, the composition of the invention is administered via injection into the soft tissue in the oral cavity and/or the craniomaxillofacial complex (CMF) of the patient.